Methods for inhibiting the growth of bacteria
AssigneeBristol-Myers Squibb Company, a Delaware Corporation
InventorsRobert McMahon, Thomas Cleary, Theresa Ochoa
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a novel method for inhibiting the growth of bacterial pathogens expressing a type III secretory system as well as enteroaggregative E. coli and/or preventing or treating an infection caused by the same. The method comprises administering to the subject an effective amount of bovine lactoferrin.
Claims63
A method for inhibiting the growth, in a subject, of a bacterial pathogen expressing a type III secretory system, the method comprising administering to the subject an effective amount of bovine lactoferrin.
A method for preventing or treating, in a subject, an infection that is caused by a bacterial pathogen expressing a type III secretory system, the method comprising administering to the subject an effective amount of bovine lactoferrin.
A method for inhibiting the adherence of bacterial pathogens expressing a type III secretory system to the intestinal wall of a subject, the method comprising administering to the subject an effective amount of bovine lactoferrin.
A method for causing the premature release of EspB in a bacterial pathogen expressing a type III secretory system, the method comprising contacting the bacterial pathogen with an effective amount of bovine lactoferrin.
A method for causing the degradation of EspB in a bacterial pathogen expressing a type III secretory system, the method comprising contacting the bacterial pathogen with an effective amount of bovine lactoferrin.
A method for inhibiting the growth of enteroaggregative E. coli in a subject, the method comprising administering to the subject an effective amount of bovine lactoferrin.
A method for preventing or treating an infection caused by enteroaggregative E. coli in a subject, the method comprising administering to the subject an effective amount of bovine lactoferrin.
A method for inhibiting the adherence of enteroaggregative E. coli to intestinal cells, the method comprising contacting the enteroaggregative E. coli with bovine lactoferrin.
An enteral formulation comprising bovine lactoferrin which has been isolated from whole milk and has a low somatic cell count.
Dependencies are inferred from the claim text.